New Mexico Tech Monitor
SEE OTHER BRANDS

Exploring the science and technology news of New Mexico

New Mexico Tech Monitor: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Tech Monitor.

Press releases published on April 28, 2025

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA’s Uniquely Efficient Internal R…

Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients …

Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting

Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting

NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced preclinical data in prostate …

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs …

XORTX Announces Grant of European Patent

XORTX Announces Grant of European Patent

CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. Dr. Luciano …

ESET announces major integration with Splunk SIEM

ESET announces major integration with Splunk SIEM

ESET PROTECT, including its Detection and Response capabilities, integrates seamlessly with Splunk SIEM. This integration empowers security admins to benefit from endpoint protection data correlated with other security insights in Splunk, facilitating …

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time to first event (all-cause mortality ( …

Atos announces the appointment of Marie de Scorbiac as Head of Investor Relations and CSR

Atos announces the appointment of Marie de Scorbiac as Head of Investor Relations and CSR

Press Release Atos announces the appointment of Marie de Scorbiac as Head of Investor Relations and CSR Paris, France – April 28, 2025 – Atos Group today announces the appointment of Marie de Scorbiac as head of investor relations and CSR. Her mission will …

Best Online Casinos Australia: MIRAX Picked as the Best Real Money Online Casino for Aussie Gamblers

Best Online Casinos Australia: MIRAX Picked as the Best Real Money Online Casino for Aussie Gamblers

PERTH, Australia, April 28, 2025 (GLOBE NEWSWIRE) -- As the online gambling sector continues to grow, finding a safe haven to gamble is getting harder than ever, especially considering the sheer number of establishments in the industry. So, we have …

Best Online Casinos Ontario: MIRAX Casino, Ranked as Top Paying Casino in 2025

Best Online Casinos Ontario: MIRAX Casino, Ranked as Top Paying Casino in 2025

TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- We tried a lot of online casinos in Ontario, but most didn’t give the bonuses we were hoping for. Then, a few locals recommended MIRAX Casino, so we decided to check it out. Right away, it felt different. The …

FreeMove Alliance und „du“ arbeiten zusammen, um multinationalen Unternehmen in den Vereinigten Arabischen Emiraten einen besseren Service zu bieten

FreeMove Alliance und „du“ arbeiten zusammen, um multinationalen Unternehmen in den Vereinigten Arabischen Emiraten einen besseren Service zu bieten

AMSTERDAM und DUBAI, Vereinigte Arabische Emirate, April 28, 2025 (GLOBE NEWSWIRE) -- FreeMove Alliance, die globale Allianz für mobile Telekommunikation zwischen Deutsche Telekom, Orange, Telia und TIM, und du, ein führender Anbieter von Festnetz-, …

FreeMove Alliance y du cooperan para prestar un mejor servicio a las multinacionales en los Emiratos Árabes Unidos

FreeMove Alliance y du cooperan para prestar un mejor servicio a las multinacionales en los Emiratos Árabes Unidos

ÁMSTERDAM y DUBÁI, Emiratos Árabes Unidos, April 28, 2025 (GLOBE NEWSWIRE) -- FreeMove Alliance, la alianza mundial de telecomunicaciones móviles entre Deutsche Telekom, Orange, Telia y TIM, y du, proveedor líder de servicios de telefonía fija, móvil y …

LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland

LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland

LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland London, 28 April 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today …

Lʼalliance FreeMove et Du coopèrent pour mieux satisfaire les besoins des multinationales aux Émirats arabes unis

Lʼalliance FreeMove et Du coopèrent pour mieux satisfaire les besoins des multinationales aux Émirats arabes unis

AMSTERDAM et DUBAI, Émirats arabes unis, 28 avr. 2025 (GLOBE NEWSWIRE) -- L’alliance FreeMove, la plus grande union internationale en matière de télécommunications mobiles conclue entre Deutsche Telekom, Orange, Telia et TIM, et Du, le plus grand …

BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025

BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025

Event titled “BV100 Shows Survival Benefit in Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter. What Does that Mean for Patients? A Perspective from the US and from Asia” Featuring Professor David Paterson and …

透過 Playio 鼓勵遊玩、擴大遊戲行銷效果

透過 Playio 鼓勵遊玩、擴大遊戲行銷效果

SUWON-SI, South Korea, April 28, 2025 (GLOBE NEWSWIRE) -- 韓國企業 GNA Company 所營運的遊戲行銷平台「Playio」,近日公開了韓國遊戲開發商 Liberty Dust 的代表作《UnderDark : Defense》行銷活動成果。 Playio 是一款連結用戶與遊戲公司的遊戲獎勵應用程式,同時也是一個遊戲行銷平台。用戶可根據自身的遊玩偏好挑選遊戲並獲得獎勵,並能將這些獎勵兌換為 LINE POINTS、Uber Eats、KFC、 …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service